AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06352762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
Study NCT02725515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb5871
Study NCT03918408 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study NCT02725515 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match XmAb5871
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered orally
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Adalimumab placebo administered SC.
Study NCT00982579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
Study NCT04394624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion
Study NCT04394624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
Study NCT04394624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
Study NCT04467957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of CFTR Modulator
Description: Inhaled contrast for MRI occurring at each visit
Study NCT04467957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon 129
Description: Inhaled contrast for MRI occurring at each visit
Study NCT02941185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Devit-3 Oral Drop
Study NCT02941185 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Devit-3 Oral Drop
Study NCT02269436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0029 infusion solution
Description: 4 µg/day, continuous i.c.v administration
Study NCT02479867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: 1 tablet from test vs 1 tablet from reference
Study NCT06017115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)
Description: Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
Study NCT06017115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)
Description: Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
Study NCT03341806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles
Study NCT03341806 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MRI-guided LITT therapy
Description: (Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
Study NCT05143242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hard tissue augmentation at the buccal aspect of single implants.
Description: One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.
Study NCT05143242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation at the buccal aspect of single implants.
Description: A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
Study NCT02081391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol oral solution 4 mg/mL
Description: Participants aged 6 months to less than 18 years old with a body weight below 20 kg received tapentadol oral solution 4 mg/mL by mouth every 4 hours for up to 72 hours.~Participants from birth to less than 6 months received tapentadol oral solution, diluted 4 fold.
Study NCT02081391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol oral solution 20 mg/mL
Description: Participants aged from 6 months to less than 18 years with a body weight greater than or equal to 20 kg received tapentadol oral solution 20 mg/mL by mouth every 4 hours for up to 72 hours.
Study NCT02081391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral solution was administered by mouth every 4 hours up to 72 hours.
Study NCT04218643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Description: IV inserted via ultrasound guidance
Study NCT04218643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: IV inserted via standard technique
Study NCT04884984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CLL1 CART
Description: Split intravenous infusion of anti-CLL1 CAR T cells \[dose escalating infusion of (5-20)x10\^6 anti-CLL1 CAR T cells/kg\].
Study NCT01190670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral and Intravenous
Study NCT01190670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Adalimumab placebo administered SC.
Study NCT03358810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PES
Description: The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
Study NCT03358810 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PES
Description: The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
Study NCT02394002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT02394002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT03484039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence
Description: Some subjects will be enrolled in a medication adherence course.
Study NCT03484039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seizure Documentation
Description: Some subjects will be enrolled in a seizure documentation course.
Study NCT03484039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Improvement
Description: Some subjects will be enrolled in a memory improvement course.
Study NCT03484039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: Some subjects will be enrolled in a stress management course.
Study NCT03184428 — intervention group
Intervention type: OTHER
Intervention: Postoperative observation and survey
Description: For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
Study NCT00560885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure Bipolar System
Description: Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
Study NCT03896867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anapod™ Humi-Therm Heated Humidification System Breathing Circuit
Description: For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue).
Study NCT03896867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger™ Warming Blanket
Description: For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue).
Study NCT04059133 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm
Description: Sham treatment (shock wave probe w/o energy)
Study NCT04059133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm
Description: Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
Study NCT00607646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
Study NCT00607646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
Study NCT02908893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-app and push notification mobile messages
Description: Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
Study NCT02908893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-app and push notification mobile messages
Description: Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
Study NCT01805700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine enhanced energy drink
Description: Comparison of different energy drinks
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib Placebo
Description: Baricitinib placebo administered orally.
Study NCT01710358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baricitinib Placebo
Description: Baricitinib placebo administered orally.
Study NCT00753350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensate™ anchored gastric device
Description: Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
Study NCT02004717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a
Study NCT00924053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001474
Description: Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
Study NCT00924053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match EGT0001474
Study NCT01963260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Study NCT01963260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8723
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Study NCT01963260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Study NCT02092857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arachidonic acid (25 mg/100 kcal )
Study NCT02092857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arachidonic acid (34 mg/100 kcal)
Study NCT02092857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
Study NCT03853187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Zr-89 labelled durvalumab PET/CT
Description: Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
Study NCT03853187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
Study NCT00965731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
Study NCT00965731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
Study NCT00965731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
Study NCT02966860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral solution OC/APAP
Study NCT03064620 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCV
Description: PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
Study NCT01805700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose drink
Description: Glucose drink (containing 84mg glucose alone)
Study NCT02284399 — intervention group
Intervention type: OTHER
Intervention: non-invasive prenatal testing
Description: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
Study NCT04079556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco LHW
Description: Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
Study NCT02868749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
Study NCT02868749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
Study NCT02868749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
Study NCT02868749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid filler
Description: Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
Study NCT02719418 — intervention group
Intervention type: DRUG
Intervention: Tinzaparin
Description: 3500 Unit or 4500 Unit subcutaneous once daily
Study NCT02314208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenbilox
Study NCT02314208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Study NCT02314208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tahor
Study NCT03722173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study NCT03722173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: Tablet
Study NCT01941368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01941368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB-FA
Study NCT02569229 — intervention group
Intervention type: OTHER
Intervention: Diagnostics for glucose tolerance with 3 different methods.
Description: 1. A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~2. An oral glucose tolerance test done within the 7 day period of CGMS.~3. Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS.
Study NCT01807819 — intervention group
Intervention type: OTHER
Intervention: Heart Failure
Description: Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
Study NCT03213041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03213041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03213041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04742244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lvemon verbena extract
Description: Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
Study NCT04742244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
Study NCT01941368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Study NCT01941368 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Interval Training